Researcher Database

Takahashi Takehiro

FacultyMedical Oncology
PositionSenior Lecturer
Last Updated :2025/04/01

Researcher

基本情報

Profile and Settings

  • 氏名

    Takahashi Takehiro

Affiliation

  • Medical Oncology, Senior Lecturer

Location

  • Fujigaoka Hospital

Degree

  • Doctor of Medical Science, Saitama Medical University, Apr. 2004

Achievements

Published Papers

  • Higher systemic exposure to unbound active metabolites of regorafenib is associated with short progression-free survival in colorectal cancer patients, KUBOTA Yutaro;FUJITA Ken-ichi;TAKAHASHI Takehiro;SUNAKAWA Yu;ISHIDA Hiroo;HAMADA Kazuyuki;ICHIKAWA Wataru;TSUNODA Takuya;SHIMADA Kazuhiro;MASUO Yusuke;KATO Yukio;SASAKI Yasutsuna, Clin Pharmacol Ther, 108(3):586 - 595, Sep. 2020, Peer-reviewed, DOI:10.1002/cpt.1810
  • Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil, SEKIDO Masae;FUJITA Ken-ichi;KUBOTA Yutaro;ISHIDA Hiroo;TAKAHASHI Takehiro;OHKUMA Ryotaro;TSUNODA Takuya;ISHIKAWA Fumihiro;SHIBANUMA Motoko;SASAKI Yasutsuna, Cancer Chemother Pharmacol, 83(6):1127 - 1135, Jun. 2019, Peer-reviewed
  • Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan., SATOH Etsuko;SASAKI Yasutsuna;OHKUMA Ryotaro;TAKAHASHI Takehiro;KUBOTA Yutaro;ISHIDA Hiroo;HAMADA Kazuyuki;KIUCHI Yuji;TSUNODA Takuya, Cancer Sci, 109(12):3896 - 3901, Dec. 2018
  • Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer., SUNAKAWA Yu;MOGUSHI Kaoru;LENZ Heinz-Josef;ZHANG Wu;TSUJI Akihito;TAKAHASHI Takehiro;DENDA Tadamichi;SHIMADA Ken;KOCHI Mitsugu;NAKAMURA Masato;KOTAKA Masahiro;SEGAWA Yoshihiko;TANIOKA Hiroaki;NEGORO Yuji;MORAN Miriana;ASTROW Stephanie H;HSIANG Jack;STEPHENS Craig;FUJII Masashi;ICHIKAWA Wataru, Mol Cancer Ther, 17(12):2788 - 2795, Dec. 2018, Peer-reviewed
  • Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer., SUNAKAWA Yu;YANG Dongyun;CAO Shu;ZHANG Wu;MORAN Miriana;ASTROW Stephanie H;HSIANG Jack;STEPHENS Craig;TSUJI Akihito;TAKAHASHI Takehiro;TANIOKA Hiroaki;NEGORO Yuji;TAKAGANE Akinori;TANI Satoshi;YAMAGUCHI Tatsuro;ETO Tetsuya;FUJII Masashi;ICHIKAWA Wataru;LENZ Heinz-Josef, Clin Colorectal Cancer, 17(4):e741 - e749, Dec. 2018, Peer-reviewed
  • Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer., SUNAKAWA Yu;YANG Dongyun;MORAN Miriana;ASTROW Stephanie H;TSUJI Akihito;STEPHENS Craig;ZHANG Wu;CAO Shu;TAKAHASHI Takehiro;DENDA Tadamichi;SHIMADA Ken;KOCHI Mitsugu;NAKAMURA Masato;KOTAKA Masahito;SEGAWA Yoshihiko;MASUISHI Toshiki;TAKEUCHI Masahiro;FUJII Masashi;NAKAJIMA Toshifusa;ICHIKAWA Wataru;LENZ Heinz-Josef, Cancer Biol Ther, 17(7):751 - 759, Jul. 2016, Peer-reviewed

Presentations

  • Comparison of cancer drug approval by PMDA in the US, SATOH Etsuko;ISHIDA Hiroo;TAKAHASHI Takehiro;KUBOTA Yutaro;KUSUMOTO Sojiro;KISHINO Yasunari;TOJO Masayuki;HAMADA Kazuyuki;SASAKI Yasutsuna, 第14回日本臨床腫瘍学会学術集会, 29 Jul. 2016, 神戸


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.